# TechTarget, Inc.: financial statements, quarterly

TTGT · Nasdaq · CIK 2018064 · [Communication](/sectors/communication.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ttgt.md) · [Financials](/companies/ttgt/financials.md) · [Filings](/companies/ttgt/filings.md) · [Insiders](/companies/ttgt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ttgt/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [59.1](/filings/0000950170-25-078416.md) | [76.5](/filings/0000950170-25-078416.md) | [58.7](/filings/0000950170-25-095465.md) | [63.0](/filings/0000950170-25-106923.md) | [62.9](/filings/0001193125-25-274316.md) | [100](/filings/0000950170-25-078416.md) | [104](/filings/0001193125-26-211990.md) | [120](/filings/0001193125-26-338065.md) | [122](/filings/0001193125-25-274316.md) | [141 d](/filings/0001193125-26-102183.md) | [106](/filings/0001193125-26-211990.md) | [116](/filings/0001193125-26-338065.md) |
| Cost of revenue | $m | [23.3](/filings/0000950170-25-078416.md) | [29.0](/filings/0000950170-25-078416.md) | [24.0](/filings/0000950170-25-095465.md) | [26.7](/filings/0000950170-25-106923.md) | [23.8](/filings/0001193125-25-274316.md) | [32.8 d](/filings/0001193125-26-102183.md) | [44.2](/filings/0001193125-26-211990.md) | [51.2](/filings/0001193125-26-338065.md) | [47.4](/filings/0001193125-25-274316.md) | [50.9 d](/filings/0001193125-26-102183.md) | [48.0](/filings/0001193125-26-211990.md) | [51.7](/filings/0001193125-26-338065.md) |
| Gross profit | $m | [35.8](/filings/0000950170-25-078416.md) | [47.4](/filings/0000950170-25-078416.md) | [34.7](/filings/0000950170-25-095465.md) | [36.3](/filings/0000950170-25-106923.md) | [39.1](/filings/0001193125-25-274316.md) | [67.6](/filings/0000950170-25-078416.md) | [59.7](/filings/0001193125-26-211990.md) | [68.8](/filings/0001193125-26-338065.md) | [74.9](/filings/0001193125-25-274316.md) | [89.8 d](/filings/0001193125-26-102183.md) | [58.0](/filings/0001193125-26-211990.md) | [64.5](/filings/0001193125-26-338065.md) |
| Research and development | $m | [2.5](/filings/0000950170-25-078416.md) | [2.7](/filings/0000950170-25-078416.md) | [3.0](/filings/0000950170-25-095465.md) | [2.9](/filings/0000950170-25-106923.md) | [2.6](/filings/0001193125-25-274316.md) | [2.9 d](/filings/0001193125-26-102183.md) | [2.8](/filings/0001193125-26-211990.md) | [2.6](/filings/0001193125-26-338065.md) | [2.9](/filings/0001193125-25-274316.md) | [2.6 d](/filings/0001193125-26-102183.md) | [3.7](/filings/0001193125-26-211990.md) | [3.4](/filings/0001193125-26-338065.md) |
| Operating income | $m | [(17.5)](/filings/0000950170-25-078416.md) | [29.2](/filings/0000950170-25-078416.md) | [(22.5)](/filings/0000950170-25-095465.md) | [(34.4)](/filings/0000950170-25-106923.md) | [(14.4)](/filings/0001193125-25-274316.md) | [(47.9)](/filings/0000950170-25-078416.md) | [(493)](/filings/0001193125-26-211990.md) | [(410)](/filings/0001193125-26-338065.md) | [(108)](/filings/0001193125-25-274316.md) | [(14.8) d](/filings/0001193125-26-102183.md) | [(81.0)](/filings/0001193125-26-211990.md) | [(22.1)](/filings/0001193125-26-338065.md) |
| Interest expense | $m | not reported | not reported | [6.2](/filings/0000950170-25-095465.md) | [6.2 d](/filings/0000950170-25-106923.md) | [5.8 d](/filings/0001193125-25-274316.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(3.1)](/filings/0000950170-25-078416.md) | [4.0](/filings/0000950170-25-078416.md) | [(7.7)](/filings/0000950170-25-095465.md) | [1.0](/filings/0000950170-25-106923.md) | [(3.6)](/filings/0001193125-25-274316.md) | [(2.2) d](/filings/0001193125-26-102183.md) | [26.4](/filings/0001193125-26-211990.md) | [(19.6)](/filings/0001193125-26-338065.md) | [(33.0)](/filings/0001193125-25-274316.md) | [(7.3) d](/filings/0001193125-26-102183.md) | [(11.4)](/filings/0001193125-26-211990.md) | [(2.0)](/filings/0001193125-26-338065.md) |
| Net income | $m | [(19.1)](/filings/0000950170-25-078416.md) | [19.4](/filings/0000950170-25-078416.md) | [(19.5)](/filings/0001193125-25-274316.md) | [(40.2)](/filings/0001193125-25-274316.md) | [(17.4)](/filings/0001193125-25-274316.md) | [(39.7)](/filings/0000950170-25-078416.md) | [(523)](/filings/0001193125-26-338065.md) | [(399)](/filings/0001193125-26-338065.md) | [(76.8)](/filings/0001193125-25-274316.md) | [(9.5) d](/filings/0001193125-26-102183.md) | [(70.8)](/filings/0001193125-26-338065.md) | [(21.7)](/filings/0001193125-26-338065.md) |
| Diluted EPS | $ per share | [(0.46)](/filings/0000950170-25-078416.md) | [0.47](/filings/0000950170-25-078416.md) | [(0.47)](/filings/0000950170-25-095465.md) | [(0.97)](/filings/0000950170-25-106923.md) | [(0.42)](/filings/0001193125-25-274316.md) | [(0.77)](/filings/0000950170-25-078416.md) | [(7.32)](/filings/0001193125-26-211990.md) | [(5.58)](/filings/0001193125-26-338065.md) | [(1.07)](/filings/0001193125-25-274316.md) | not reported | [(0.98)](/filings/0001193125-26-211990.md) | [(0.30)](/filings/0001193125-26-338065.md) |
| Basic EPS | $ per share | [(0.46)](/filings/0000950170-25-078416.md) | [0.47](/filings/0000950170-25-078416.md) | [(0.47)](/filings/0000950170-25-095465.md) | [(0.97)](/filings/0000950170-25-106923.md) | [(0.42)](/filings/0001193125-25-274316.md) | [(0.77)](/filings/0000950170-25-078416.md) | [(7.32)](/filings/0001193125-26-211990.md) | [(5.58)](/filings/0001193125-26-338065.md) | [(1.07)](/filings/0001193125-25-274316.md) | not reported | [(0.98)](/filings/0001193125-26-211990.md) | [(0.30)](/filings/0001193125-26-338065.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2022-12-31) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [10.8](/filings/0000950170-25-078416.md) | not reported | not reported | not reported | [276](/filings/0001193125-26-102183.md) | [78.7](/filings/0000950170-25-095465.md) | [61.7](/filings/0000950170-25-106923.md) | [46.3](/filings/0001193125-25-274316.md) | [40.6](/filings/0001193125-26-338065.md) | [47.7](/filings/0001193125-26-211990.md) | [45.8](/filings/0001193125-26-338065.md) |
| Current assets | $m | not reported | [166](/filings/0000950170-25-078416.md) | not reported | not reported | not reported | [456](/filings/0001193125-26-102183.md) | [175](/filings/0000950170-25-095465.md) | [168](/filings/0000950170-25-106923.md) | [162](/filings/0001193125-25-274316.md) | [155](/filings/0001193125-26-338065.md) | [148](/filings/0001193125-26-211990.md) | [144](/filings/0001193125-26-338065.md) |
| Total assets | $m | not reported | [928](/filings/0000950170-25-078416.md) | not reported | not reported | [0.0](/filings/0001193125-24-255930.md) | [2,266](/filings/0001193125-26-102183.md) | [1,506](/filings/0000950170-25-095465.md) | [1,097](/filings/0000950170-25-106923.md) | [987](/filings/0001193125-25-274316.md) | [937](/filings/0001193125-26-338065.md) | [878](/filings/0001193125-26-211990.md) | [853](/filings/0001193125-26-338065.md) |
| Current liabilities | $m | not reported | [595](/filings/0000950170-25-078416.md) | not reported | not reported | not reported | [535](/filings/0001193125-26-102183.md) | [183](/filings/0000950170-25-095465.md) | [175](/filings/0000950170-25-106923.md) | [143](/filings/0001193125-25-274316.md) | [127](/filings/0001193125-26-338065.md) | [128](/filings/0001193125-26-211990.md) | [125](/filings/0001193125-26-338065.md) |
| Total liabilities | $m | not reported | [982](/filings/0000950170-25-078416.md) | not reported | not reported | [0.0](/filings/0001193125-24-255930.md) | [695](/filings/0001193125-26-102183.md) | [450](/filings/0000950170-25-095465.md) | [428](/filings/0000950170-25-106923.md) | [389](/filings/0001193125-25-274316.md) | [343](/filings/0001193125-26-338065.md) | [353](/filings/0001193125-26-211990.md) | [347](/filings/0001193125-26-338065.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [417](/filings/0000950170-25-078416.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(14.3)](/filings/0001193125-26-102183.md) | [(54.3)](/filings/0001193125-26-102183.md) | [(74.4)](/filings/0001193125-25-274316.md) | [(92.5)](/filings/0001193125-25-274316.md) | [134](/filings/0001193125-25-274316.md) | [1,572](/filings/0001193125-26-338065.md) | [1,056](/filings/0001193125-26-338065.md) | [669](/filings/0001193125-26-338065.md) | [598](/filings/0001193125-25-274316.md) | [595](/filings/0001193125-26-338065.md) | [525](/filings/0001193125-26-338065.md) | [507](/filings/0001193125-26-338065.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(13.9) d](/filings/0000950170-25-078416.md) | [(17.4) d](/filings/0001193125-26-102183.md) | [(1.8)](/filings/0000950170-25-095465.md) | [(29.3) d](/filings/0000950170-25-106923.md) | [(4.6) d](/filings/0001193125-25-274316.md) | [(29.2) d](/filings/0001193125-26-102183.md) | [12.2](/filings/0001193125-26-211990.md) | [1.5 d](/filings/0001193125-26-338065.md) | [(9.1) d](/filings/0001193125-25-274316.md) | [11.8 d](/filings/0001193125-26-102183.md) | [(0.1)](/filings/0001193125-26-211990.md) | [3.4 d](/filings/0001193125-26-338065.md) |
| Capital expenditure | $m | not reported | not reported | [0.1](/filings/0000950170-25-095465.md) | [0.2 d](/filings/0000950170-25-106923.md) | [0.0 d](/filings/0001193125-25-274316.md) | [0.1 d](/filings/0001193125-26-102183.md) | [0.0](/filings/0001193125-26-211990.md) | [0.1 d](/filings/0001193125-26-338065.md) | [0.1 d](/filings/0001193125-25-274316.md) | [0.2 d](/filings/0001193125-26-102183.md) | [0.1](/filings/0001193125-26-211990.md) | [2.0 d](/filings/0001193125-26-338065.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [41.7](/filings/0000950170-25-095465.md) | [41.7](/filings/0000950170-25-106923.md) | [41.7](/filings/0001193125-25-274316.md) | [71.5](/filings/0001193125-26-211990.md) | [71.5](/filings/0001193125-26-338065.md) | [71.8](/filings/0001193125-25-274316.md) | [72.3](/filings/0001193125-26-211990.md) | [72.3](/filings/0001193125-26-338065.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 72,332,660 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338065.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.